{
    "clinical_study": {
        "@rank": "38490", 
        "arm_group": [
            {
                "arm_group_label": "Metformin 500 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Metformin HCl 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks."
            }, 
            {
                "arm_group_label": "Alogliptin 12.5 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks."
            }, 
            {
                "arm_group_label": "Alogliptin 12.5mg and metformin 500mg FDC", 
                "arm_group_type": "Experimental", 
                "description": "Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of alogliptin and metformin\n      fixed-dose combination (FDC) as compared with alogliptin alone or metformin alone on Type 2\n      Diabetes Mellitus (T2DM)."
        }, 
        "brief_title": "Efficacy and Safety of Alogliptin and Metformin Fixed-dose Combination in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "The drug being tested in this study is a fixed-dose combination tablet of alogliptin and\n      metformin to treat people who have diabetes. This study will look at glycemic control in\n      people who take alogliptin and metformin FDC compared with alogliptin or metformin alone.\n      The study will enroll approximately 640 patients. Participants will be randomly assigned (by\n      chance, like flipping a coin) to one of the four treatment groups\u2014which will remain\n      undisclosed to the patient and study doctor during the study (unless there is an urgent\n      medical need):\n\n        -  Alogliptin 12.5 mg twice daily (BID)\n\n        -  Metformin HCL 500 mg BID\n\n        -  Alogliptin 12.5 mg and Metformin HCL 500 mg FDC BID\n\n        -  Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has\n           no active ingredient.\n\n      All participants will be asked to take 2 tablets and 1 capsule twice a day at the same time\n      each day throughout the study. All participants will be asked to record any hypoglycemic\n      events in a diary. This multi-centre trial will be conducted in China, South Korea, and\n      Malaysia. The overall time to participate in this study is 34 weeks. Participants will make\n      11 visits to the clinic."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Capable of understanding and complying with protocol requirements.\n\n          2. The participant or, when applicable, the participant's legally acceptable\n             representative signs and dates a written, informed consent form and any required\n             privacy authorization prior to the initiation of any study procedures.\n\n          3. Has a historical diagnosis of T2DM.\n\n          4. Male or female and aged 18 to 75 years, inclusive.\n\n          5. Body mass index (BMI) between 20 and 45 kg/m^2, inclusive.\n\n          6. A female of childbearing potential who is sexually active with a nonsterilized male\n             partner agrees to use routinely adequate contraception from signing of informed\n             consent throughout the duration of the study.\n\n          7. Is experiencing inadequate glycemic control defined as HbA1c concentration between\n             7.5% and 10%, inclusive, and has been treated with diet and exercise for at least 2\n             months prior to Screening. (Exception: a participant who has received any other\n             diabetic therapy for less than 7 days in total  within the 2 months prior to the\n             screening, can be included).\n\n          8. If male, has a hemoglobin >12 g/dL (>120 g/L) at Screening or if female, has a\n             hemoglobin >10 g/dL (>100 g/L) at Screening.\n\n          9. If male, has a serum creatinine <1.5 mg/dL at Screening or if female, has a serum\n             creatinine <1.4 mg/dL at Screening, and estimated glomerular filtration rate (eGFR)\n             >60 mL/min/1.73 m^2 based on calculation using the Modification of Diet in Renal\n             Disease (MDRD) at Screening.\n\n         10. Willing and able to monitor their own blood glucose concentrations using a home\n             glucose monitor and complete a subject diary.\n\n        Exclusion Criteria:\n\n          1. Participated in another clinical study within 90 days prior to Screening.\n\n          2. Received any investigational compound within 30 days prior to Randomization.\n\n          3. Received a dipeptidyl peptidase-4 (DPP-4) inhibitor within 3 months prior to\n             screening.\n\n          4. History of laser treatment for proliferative diabetic retinopathy within the 6 months\n             prior to Screening.\n\n          5. History of treatment for diabetic gastric paresis, gastric banding, or gastric bypass\n             surgery.\n\n          6. History of diabetic ketoacidosis or hyperosmolar non-ketotic coma.\n\n          7. Chronic pancreatitis and/or history of acute pancreatitis.\n\n          8. Systolic blood pressure >180 mmHg and/or diastolic blood pressure >110 mmHg at\n             Screening.\n\n          9. History of any hemoglobinopathy or diagnosis of chronic anemia.\n\n         10. New York Heart Association Class III or IV heart failure. (Participants who are\n             stable at Class I or II and are currently treated, are candidates for the study.)\n\n         11. History of coronary angioplasty, coronary stent placement, coronary bypass surgery,\n             or myocardial infarction within 6 months prior to Screening.\n\n         12. History of any cancer, other than squamous cell or basal cell carcinoma of the skin,\n             which has not been in full remission for at least 5 years prior to Screening.\n             Participants with a history of treated cervical intraepithelial neoplasia [CIN] I or\n             CIN II are allowed.\n\n         13. Significant clinical sign or symptom of hepatopathy, acute or chronic hepatitis,\n             human immunodeficiency virus or alanine aminotransferase (ALT) is 2.5 times above\n             upper limit of normal value.\n\n         14. History of angioedema in association with use of angiotensin-converting enzyme\n             inhibitors (ACEI) or angiotensin II receptor blockers (ARB).\n\n         15. History of hypersensitivity or allergies to any DPP-4 inhibitor and/or metformin or\n             related compounds.\n\n         16. Has used oral or systemically injected glucocorticoids (including intra-articular\n             injection) or has used weight-loss drugs within 2 months prior to Screening. (Inhaled\n             or topical corticosteroids were allowed.)\n\n         17. History of alcohol or substance abuse within 2 years prior to Screening.\n\n         18. Has used medicine for weight loss within 60 days prior to Screening (such as Xenical,\n             Sibutramine, Phenylpropanolamine or similar nonprescription drugs).\n\n         19. History of organ transplantation.\n\n         20. Is an immediate family member, study site employee, or is in a dependant relationship\n             with a study site employee who is involved in conduct of this study (eg, spouse,\n             parent, child, sibling) or may consent under duress.\n\n         21. Has, in the judgment of the investigator, any major illness or debility that may\n             prohibit the participant from completing the study.\n\n         22. If female, is pregnant or lactating or intending to become pregnant before, during,\n             or within 1 month after participating in this study; or intending to donate ova\n             during such time period."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "640", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01890122", 
            "org_study_id": "SYR-322MET_303", 
            "secondary_id": [
                "U1111-1139-0497", 
                "NMRR-12-799-12754", 
                "CTR20130254"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Alogliptin 12.5 mg", 
                "description": "Alogliptin tablets.", 
                "intervention_name": "Alogliptin", 
                "intervention_type": "Drug", 
                "other_name": "SYR-322; Nesina"
            }, 
            {
                "arm_group_label": "Metformin 500 mg", 
                "description": "Metformin capsules.", 
                "intervention_name": "Metformin HCl", 
                "intervention_type": "Drug", 
                "other_name": "Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet"
            }, 
            {
                "arm_group_label": "Alogliptin 12.5mg and metformin 500mg FDC", 
                "description": "Aloglptin and metformin FDC tablets.", 
                "intervention_name": "Alogliptin and Metformin fixed-dose combination (FDC)", 
                "intervention_type": "Drug", 
                "other_name": "Kazano"
            }, 
            {
                "arm_group_label": [
                    "Metformin 500 mg", 
                    "Alogliptin 12.5mg and metformin 500mg FDC", 
                    "Placebo"
                ], 
                "description": "Alogliptin placebo-matching tablets.", 
                "intervention_name": "Alogliptin placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Alogliptin 12.5 mg", 
                    "Alogliptin 12.5mg and metformin 500mg FDC", 
                    "Placebo"
                ], 
                "description": "Metformin placebo-matching capsules.", 
                "intervention_name": "Metformin placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Metformin 500 mg", 
                    "Alogliptin 12.5 mg", 
                    "Placebo"
                ], 
                "description": "Alogliptin and metformin FDC placebo-matching tablets.", 
                "intervention_name": "Alogliptin and metformin FDC placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Alogliptin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Drug therapy", 
        "lastchanged_date": "March 24, 2014", 
        "link": {
            "description": "The Alogliptin-Metformin Fixed Dose Combination (KAZANO) were recently approved in the United States (US) on 25 January 2013.", 
            "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203414s000lbl.pdf"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanning", 
                        "country": "China", 
                        "state": "Guangxi"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hengshui", 
                        "country": "China", 
                        "state": "Hebei"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shijiazhuang", 
                        "country": "China", 
                        "state": "Hebei"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shiyan", 
                        "country": "China", 
                        "state": "Hubei"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yueyang", 
                        "country": "China", 
                        "state": "Hunan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changzhou", 
                        "country": "China", 
                        "state": "Jiangsu"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suzhou", 
                        "country": "China", 
                        "state": "Jiangsu"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanchang", 
                        "country": "China", 
                        "state": "Jiangxi"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China", 
                        "state": "Jilin"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shanxi"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wenzhou", 
                        "country": "China", 
                        "state": "Zhejiang"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goyang-si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeonju-si, Jeollabuk-do", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johor Bahru", 
                        "country": "Malaysia", 
                        "state": "Johor"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alor Setar", 
                        "country": "Malaysia", 
                        "state": "Kedah Darul Aman"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kubang Kerian", 
                        "country": "Malaysia", 
                        "state": "Kelantan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ipoh", 
                        "country": "Malaysia", 
                        "state": "Perak"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Korea, Republic of", 
                "Malaysia"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin and Metformin Fixed Dose Combination, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "800-778-2860"
        }, 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Malaysia: Ministry of Health", 
                "South Korea: Institutional Review Board", 
                "China: Food and Drug Administration", 
                "China: Ethics Committee", 
                "China: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week  26 or early termination.", 
            "measure": "Change From Baseline to Week 26 (or Early Termination) in Glycosylated Hemoglobin (HbA1c)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01890122"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change From Baseline in HbA1c Over Time", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Weeks 4, 8, 12, 16 and 20"
            }, 
            {
                "measure": "Change From Baseline in Fasting Plasma Glucose Over Time", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Weeks 4, 8, 12, 16, 20 and 26"
            }, 
            {
                "description": "Rescue is defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 7 days of first sample:  -After > 1 week of treatment but prior to Week 4 visit: A single fasting plasma glucose (FPG) \u2265275 mg/dL (\u226515.27 mmol/L); -From the Week 4 but prior to the Week 8 visit: A single FPG \u2265250 mg/dL (\u226513.88 mmol/L); -From the Week 8 visit but prior to the Week 12 visit: A single FPG \u2265225 mg/dL (\u226512.49 mmol/L); -From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c \u22658.5% and \u22640.5% reduction in HbA1c from baseline.", 
                "measure": "Time to hyperglycemic rescue event", 
                "safety_issue": "No", 
                "time_frame": "From the date of randomization through Week 26"
            }, 
            {
                "description": "Rescue is defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 7 days of first sample:  -After > 1 week of treatment but prior to Week 4 visit: A single fasting plasma glucose (FPG) \u2265275 mg/dL (\u226515.27 mmol/L); -From the Week 4 but prior to the Week 8 visit: A single FPG \u2265250 mg/dL (\u226513.88 mmol/L); -From the Week 8 visit but prior to the Week 12 visit: A single FPG \u2265225 mg/dL (\u226512.49 mmol/L); -From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c \u22658.5% and \u22640.5% reduction in HbA1c from baseline.", 
                "measure": "Percentage of Participants Meeting Rescue Criteria", 
                "safety_issue": "No", 
                "time_frame": "Weeks 4, 8, 12, 16 and 26"
            }, 
            {
                "description": "Marked hyperglycemia is defined as a fasting plasma glucose level \u2265 200 mg/dL (11.1 mmol/L).", 
                "measure": "Percentage of Participants With Marked Hyperglycemia", 
                "safety_issue": "No", 
                "time_frame": "Weeks 4, 8, 12, 16, 20 and 26"
            }, 
            {
                "measure": "Change From Baseline in Body Weight Over Time", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Weeks 12 and 26"
            }, 
            {
                "description": "Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c less than or equal to 6.5%.", 
                "measure": "Percentage of Participants With Glycosylated Hemoglobin \u2264 6.5%", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }, 
            {
                "description": "Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c less than or equal to 7%.", 
                "measure": "Percentage of Participants With Glycosylated Hemoglobin \u2264 7.0%", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }, 
            {
                "description": "Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c less than or equal to 7.5%.", 
                "measure": "Percentage of Participants With Glycosylated Hemoglobin \u2264 7.5%", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }, 
            {
                "description": "Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5%.", 
                "measure": "Percentage of Participants With a Decrease in Glycosylated Hemoglobin \u2265 0.5%", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "description": "Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.0%.", 
                "measure": "Percentage of Participants With a Decrease in Glycosylated Hemoglobin \u2265 1.0%", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "description": "Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5%.", 
                "measure": "Percentage of Participants With a Decrease in Glycosylated Hemoglobin \u2265 1.5%", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "description": "Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0%.", 
                "measure": "Percentage of Participants With a Decrease in Glycosylated Hemoglobin \u2265 2.0%", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}